Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (MDLN), Mirum Pharmaceuticals (MIRM) and Alcon (ALC)

Tipranks - Tipranks - Fri Feb 27, 7:32AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medline, Inc. Class A (MDLN – Research Report), Mirum Pharmaceuticals (MIRM – Research Report) and Alcon (ALC – Research Report).

Claim 50% Off TipRanks Premium

Medline, Inc. Class A (MDLN)

In a report released yesterday, David Roman from Goldman Sachs maintained a Buy rating on Medline, Inc. Class A, with a price target of $49.00. The company’s shares closed last Wednesday at $48.18.

According to TipRanks.com, Roman is a 1-star analyst with an average return of -3.1% and a 43.9% success rate. Roman covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., GE Healthcare Technologies Inc, and Shoulder Innovations, Inc. ;'>

Medline, Inc. Class A has an analyst consensus of Strong Buy, with a price target consensus of $50.08, which is a 5.7% upside from current levels. In a report issued on February 12, Evercore ISI also maintained a Buy rating on the stock with a $50.00 price target.

See today’s best-performing stocks on TipRanks >>

Mirum Pharmaceuticals (MIRM)

In a report released yesterday, Joe Johoon Kim from RBC Capital maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $128.00. The company’s shares closed last Wednesday at $108.62.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $118.00 average price target, implying a 9.5% upside from current levels. In a report released today, TipRanks – DeepSeek also upgraded the stock to Buy with a $121.00 price target.

Alcon (ALC)

In a report released today, Steven Lichtman from William Blair maintained a Hold rating on Alcon. The company’s shares closed last Wednesday at $86.27.

According to TipRanks.com, Lichtman is a 5-star analyst with an average return of 12.7% and a 51.9% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Sight Sciences, and RxSight. ;'>

Currently, the analyst consensus on Alcon is a Moderate Buy with an average price target of $96.34.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).